Hsinchu Science Park with new technology and biomedical investments

Taiwan's Hsinchu Science Park region has approved six major investment projects totaling NT$1.83 billion (US$63.3 million), spanning advanced semiconductor packaging, display technology, optical manufacturing, and biomedical innovations.

Winstek Semiconductor leads with NT$800 million for developing 2.5D/3D wafer and IC testing technologies for AI computing, automotive electronics, and 5G applications. The company specialises in heterogeneous integration and TSV (through-silicon via) technology that reduces customer costs and lead times.

Rayleigh Vision Intelligence will invest NT$500 million in micro LED technology using AI-driven processes for AR/VR headsets and wearables, with potential expansion into silicon photonics. Optoway Technology's NT$100 million investment targets high-speed laser modules for data centers and AI networks, leveraging its unique position as Taiwan's only company developing both laser chips and modules.

Apexlens will invest NT$210 million in a smart automated factory for ultra-precision optical manufacturing and silicone hydrogel contact lens production, with regulatory approval across multiple international markets. In the biomedical sector, Phalanx Biotech Group will invest NT$120 million producing high-density gene chips for hereditary testing and maternal health applications, while Expercy Medical's NT$100 million investment focuses on anti-adhesion medical devices including innovative thermoresponsive hydrogel technology.

These investments reinforce Taiwan's semiconductor leadership while expanding capabilities in emerging technologies, positioning Hsinchu as a comprehensive technology ecosystem serving global markets.